

DAYBUE[®] and DAYBUE[®] STIX Prescription and Enrollment Form Overview

A helpful guide for completing and submitting DAYBUE and DAYBUE STIX prescriptions

The **Prescription and Enrollment Form** is used to prescribe DAYBUE or DAYBUE STIX to patients **AND** have parents/legal guardians provide consent to enroll their loved one in the Acadia Connect[®] patient and family support program's full suite of services.

Review all sections of the **Prescription and Enrollment Form**.

The prescribing physician (or office staff) and the patient's parent/legal guardian should complete and sign where indicated.

Fax or email the completed form to Acadia Connect at **1-888-385-2748** or **DAYBUE@AcadiaConnect.com**.

You will receive a receipt of enrollment and a Patient Access Manager will reach out within 24 hours.

Completing Page 1 Patient and Parent/Legal Guardian Information

PRESCRIPTION AND ENROLLMENT FORM

Healthcare providers:

- Please submit completed enrollment form, copy of all insurance cards (front and back), and copy of patient's clinical chart notes to Acadia Connect[®]
- Have the parent/legal guardian read pages 3-5 and sign where indicated
- Fax the completed form to Acadia Connect at 1-888-385-2748
- If your office has not received a confirmation fax that your enrollment form has been received within one (1) business day after submission, please resubmit or call Acadia Connect at 1-844-737-2223, Monday to Friday, 8AM to 8PM ET

1 PATIENT AND PARENT/LEGAL GUARDIAN INFORMATION

PATIENT INFORMATION

First Name: Jane Middle Initial: _____ Last Name: Smith
 Address: 123 Fulton Street City: Cleveland State: OH ZIP Code: 12345
 Date of Birth (MM/DD/YYYY): 01/01/2013 Gender: Female

PARENT/LEGAL GUARDIAN INFORMATION

First Name: John Last Name: Smith
 Relationship to Patient: Father Preferred Language: English Spanish Other _____
 Home Phone #: (123) 456-7891 Mobile Phone #: (123) 456-7891
 Work Phone #: (123) 456-7891 Preferred Phone #: Home Work Mobile
 Best Time to Call: Morning Afternoon Evening Can We Leave a Message? Yes No
 Email Address: john.smith@email.com

2 INSURANCE INFORMATION No insurance

Primary Medical Insurance Name: Aetna
 Policy #: W123456789 Group #: 123456-789-10112 Phone #: 1-800-123-4567
 Policy Holder's Full Name: John Smith
 Date of Birth (MM/DD/YYYY): 01/01/1980 Relationship to Patient: Father
Prescription Drug Insurance Name: Aetna Rx Phone #: _____
 Rx Group #: 123456 Rx PCN #: 123456 Rx BIN #: 123456

Secondary Medical Insurance Name: _____
 Policy #: _____ Group #: _____ Phone #: _____
 Policy Holder's Full Name: _____
 Date of Birth (MM/DD/YYYY): _____ Relationship to Patient: _____
 Prescription Drug Insurance Name: _____ Rx Phone #: _____
 Rx Group #: _____ Rx PCN #: _____ Rx BIN #: _____

3 PRESCRIBER INFORMATION

Prescriber First Name: Steve Last Name: Michaels
 Prescriber Specialty: Healthcare provider Practice Name: Ohio Commons Hospital
 Address: 111 Cardinal Drive City: Cleveland State: OH ZIP Code: 12345
 NPI #: 12345678987654 Medical Provider ID #: 1234321565 DEA #: HM1234567
 Phone #: (123) 456-7891 Fax #: (123) 456-7891
 Office Contact: John Doe Contact Phone #: (123) 456-7891 Office Email: john.doe@email.com

- A

Instructions for submitting the form to Acadia Connect.
- B

Complete this section with general contact information about the patient and their parent/legal guardian.
- C

If the patient is covered under both medical and pharmacy insurance, and/or has any secondary medical insurance, include information for all applicable plans. Having this information upfront can help complete the benefits investigation in a timely manner.

The information completed in this sample form is an example only. It does not reflect an actual patient or healthcare provider.

Completing Page 2

Prescriber, Clinical, and Prescription Information



PRESCRIPTION AND ENROLLMENT FORM

acadia connect | Daybue (trofinetide) oral solution | Daybue Stix (trofinetide) for oral solution

Patient's Name: Jane Smith Date of Birth (MM/DD/YYYY): 01/01/2013

4 CLINICAL INFORMATION

Applicable ICD-10 Code: F84.2 Has the Patient Had Genetic Testing? (methyl-CpG binding protein 2 [MECP2]) No Yes Date of Test: 01/23/2025

Genetic Test Company: _____

Genetic Test Results: _____

Does the patient have known renal impairment? No Yes Current eGFR level: 60 mL/min/1.73 m²

5 PHARMACY PRESCRIPTION

Patient's Weight (kg): _____ Administration: Oral Gastrostomy Tube Type: ENFit® Luer Lock Syringe

DAYBUE® STIX (trofinetide) for oral solution DAYBUE® (trofinetide) 200 mg/mL, oral solution

Day Supply: _____ Refills: _____ Day Supply: _____ Refills: _____

Please select the appropriate dosage for the patient by selecting one box.

Patient Weight	DAYBUE Dosage	STIX Packet Strength
<input type="checkbox"/> 9 kg to <12 kg	5,000 mg twice daily	5,000 mg packets
<input type="checkbox"/> 12 kg to <20 kg	6,000 mg twice daily	6,000 mg packets
<input type="checkbox"/> 20 kg to <35 kg	8,000 mg twice daily	8,000 mg packets
<input type="checkbox"/> 35 kg to <50 kg	10,000 mg twice daily	5,000 mg packets
<input type="checkbox"/> 50 kg or more	12,000 mg twice daily	6,000 mg packets
<input type="checkbox"/> Other dosage	_____ mg twice daily	_____ mg packets

OR

Patient Weight	DAYBUE Dosage	Oral Solution
<input type="checkbox"/> 9 kg to <12 kg	5,000 mg twice daily	25 mL per dose
<input type="checkbox"/> 12 kg to <20 kg	6,000 mg twice daily	30 mL per dose
<input type="checkbox"/> 20 kg to <35 kg	8,000 mg twice daily	40 mL per dose
<input type="checkbox"/> 35 kg to <50 kg	10,000 mg twice daily	50 mL per dose
<input type="checkbox"/> 50 kg or more	12,000 mg twice daily	60 mL per dose
<input type="checkbox"/> Other dosage	_____ mg twice daily	_____ mL per dose

The specialty pharmacy will provide the caregiver with necessary instructions on dilution volume and administration, unless noted in the Additional Prescribing Directions below.

Additional Prescribing Directions (eg, dose adjustment, DAYBUE STIX in mg and DAYBUE oral solution in mL): _____

Patient's Allergies: NKDA Please List: _____

Current Medications: valproate oral solution

In their monthly shipments, all patients will receive ancillary materials required for the treatment method selected by the prescriber.

6 PRESCRIBER AUTHORIZATION

I attest that I have obtained written permission, in the event it is required under applicable federal and/or state law, of my patient (or the patient's legal representative) for the release of my patient's Protected Health Information ("PHI") to Acadia Pharmaceuticals Inc. or its representatives or agents (collectively "Acadia") as may be necessary for the patient's participation in a program designed to assist patients in determining their insurance coverage for DAYBUE that I have elected to prescribe. I direct Acadia to convey, on my behalf, any prescription-related PHI and other prescribing information delivered to Acadia for DAYBUE to the dispensing pharmacy chosen by or for the patient, to the patient's health insurance company, and to other third parties as may be necessary for dispensing the patient's prescription for DAYBUE, with verifying the patient's insurance coverage for DAYBUE, providing information regarding payer coverage and benefits and how to prepare prior authorization requests, coverage determination appeals, or other coverage issues, and/or assisting with patient assistance and support or reduced-cost DAYBUE. I understand I am to comply with the state-specific prescription requirements such as e-prescribing, state-specific prescription form, fax language, etc. I agree that Acadia may contact me for additional information relating to DAYBUE, including but not limited to via email, fax, and telephone. I appoint Acadia as my agent for the purpose of conveying this prescription to the appropriate dispensing pharmacy. I certify that DAYBUE is medically necessary and in the best interest of the named patient.

My signature below certifies that I have read, understand, and agree to the Prescriber Authorization statement above.

Sign Here Signature (Dispense as Written): [Signature] No Stamp Signature Date: 05/01/2025

OR

Sign Here Signature (Substitution Allowed): _____ No Stamp Signature Date: _____

Print Name: Dr. Steve Michaels

©2024 Acadia Pharmaceuticals Inc. Acadia, Acadia Connect and DAYBUE are registered trademarks of Acadia Pharmaceuticals Inc. All rights reserved. DAY-US-0438-v3 03/24. 2 of 5

The information completed in this sample form is an example only. It does not reflect an actual patient or healthcare provider.

D Include the patient's name and date of birth (DOB) at the top of every page.

E Note whether the patient has undergone genetic testing or has renal impairment. Be sure to include all related genetic testing information where indicated and eGFR level. If you select "No" for either, you do not have to list this information.

F • Reminder: DAYBUE and DAYBUE STIX are not recommended for patients with severe renal impairment. For patients with moderate renal impairment who require a dose less than 5,000 mg, DAYBUE oral solution is recommended.¹ See the [Prescribing Information](#) for complete dosage recommendations in patients with renal impairment.

G Complete the prescription section by

- Providing the patient's weight, the manner of administration, and recommended syringe
- Selecting the preferred formulation and appropriate weight-based dosage
- Using the "Additional Prescribing Directions" lines to include any possible dose adjustments
 - Dosing for DAYBUE STIX should be written in milligrams (mg)
 - Dosing for DAYBUE oral solution should be written in milliliters (mL)

Helpful resources:

- Please refer to the [Prescribing Information](#) and [online dosing tool](#) for dosing, assistance with dose modifications, or switching patients from DAYBUE oral solution to DAYBUE STIX




Prescribers must sign this section for the prescription form to be valid. Stamp signatures are not allowed as they may cause delays in the enrollment process. **Optional:** To electronically sign the form, prescribers should utilize the "Fill and Sign" feature on Adobe Acrobat (Reader version or better). Click "Add Signature," followed by "Draw," and use a mouse or fingertip to sign.

Completing Page 3

Patient/Parent/Legal Guardian HIPAA Authorization



PRESCRIPTION AND ENROLLMENT FORM

Patient's Name: Jane Smith Date of Birth (MM/DD/YYYY): 01/01/2013

7 ADDITIONAL HEALTHCARE PROVIDERS (Please complete the table with information to the best of your knowledge.)

CARE TEAM MEMBER ROLES	PROVIDER OFFICE	NAME	OFFICE PHONE/FAX
	Cleveland Pediatrics	Jack Adams	1-888-123-4567

8 PATIENT/PARENT/LEGAL GUARDIAN AUTHORIZATION FOR DISCLOSURE OF HEALTH INFORMATION
(Please read and sign on the next page if you agree.)

I hereby authorize and direct my child's or ward's (collectively, "child's") healthcare providers (including physicians, prescribers, providers of long-term care, and pharmacies) and health insurance companies, and each of their respective representatives, employees, staff, and agents (collectively "Providers") to use my child's Protected Health Information ("PHI") and/or disclose it to Acadia Pharmaceuticals Inc. and its representatives and agents (collectively "Acadia") to assist with my child obtaining DAYBUE and Acadia Connect Support Services (we refer to Acadia Connect and the Acadia Copay Card Program collectively as "Acadia Connect Support Services" or the "Program"). I understand that this PHI may include, but is not limited to, name, address, phone number, and other contact information; information relating to my child's medical condition, treatment, care management, and health insurance; as well as information provided on this authorization and any prescription. I understand that pharmacies may receive remuneration (payment) from Acadia for providing patient support services and disclosing associated PHI to Acadia pursuant to this authorization.

I further authorize Acadia to use health information it collects about my child, and to disclose it to third parties, including, but not limited to, specialty pharmacies, health plans, insurance companies, and patient assistance programs in relation to my child's obtaining DAYBUE and/or participating in the Program, including communicating with me and my child about the Program; investigating insurance benefits, eligibility, and coverage; providing financial assistance for copay or out-of-pocket payments; assessing eligibility for free medication supply; coordinating care; and coordinating the delivery of medication. I also authorize Acadia to disclose to my child's Providers for Program purposes any information about me and my child that Acadia may create or receive.

©2026 Acadia Pharmaceuticals Inc. Acadia, Acadia Connect and DAYBUE are registered trademarks of Acadia Pharmaceuticals Inc. All rights reserved. DAY-US-0438-v3 03/26.

3 of 5

H Include the patient's name and DOB at the top of every page.

I The parent/legal guardian should list the names and contact information for any other healthcare providers that may be part of the patient's care team. Examples include a pediatrician, family or internal medicine, neurologist, gastroenterologist, or other healthcare providers.

J The parent/legal guardian should read this section on pages 3 and 4 to provide authorization for disclosure of health information for the patient.

The information completed in this sample form is an example only. It does not reflect an actual patient or healthcare provider.

HIPAA=Health Insurance Portability and Accountability Act.

Completing Page 4

Patient/Parent/Legal Guardian HIPAA Authorization (cont'd)



PRESCRIPTION AND ENROLLMENT FORM

acadia connect | Daybue® (trofinetide) oral solution | Daybue Stix® (trofinetide) for oral solution

Patient's Name: Jane Smith Date of Birth (MM/DD/YYYY): 01/01/2013

8 PATIENT/PARENT/LEGAL GUARDIAN AUTHORIZATION FOR DISCLOSURE OF HEALTH INFORMATION (cont)
(Please read and sign below if you agree.)

I understand that once my child's PHI or other information about my child is disclosed to or by Acadia pursuant to this authorization, it may no longer be protected by state and federal privacy laws and may be subject to re-disclosure. I understand that I may refuse to sign this authorization, and my refusal will not affect the treatment my child receives from my child's Providers, nor will it affect my child's enrollment or eligibility for health insurance benefits to which my child is otherwise entitled. However, if I refuse to sign this authorization on behalf of my child, my child will not be able to participate in the Program, as the disclosures of my child's PHI and other information about my child by my child's Providers and Acadia for Program purposes are necessary to facilitate my child's participation in the Program. I also understand that I may cancel (revoke) this authorization at any time by calling 844-737-2223 or by mailing Acadia Connect, 1710 Shelby Oaks Dr. Ste 3, Memphis, TN 38134; however, this cancellation will not apply to any PHI or other information already used or disclosed in reliance on this authorization before notice of the cancellation is received. I understand that this authorization is valid for a period of 10 years or for a shorter period dictated by applicable state law. I understand that my child and I have a right to receive and will be provided with a signed copy of this authorization by Acadia. I may request additional copies by contacting Acadia by calling 844-737-2223 or by mailing Acadia Connect, 1710 Shelby Oaks Dr. Ste 3, Memphis, TN 38134.

Sign Here Patient/Parent/Legal Guardian: John Smith Date: 05/01/2025
Name: John Smith Relationship to Patient: Father

©2026 Acadia Pharmaceuticals Inc. Acadia, Acadia Connect and DAYBUE are registered trademarks of Acadia Pharmaceuticals Inc. All rights reserved. DAY-US-0638-v3 03/26. 4 of 5

K

Include the patient's name and DOB at the top of every page.

L

Parents/legal guardians must read and sign this section.

Optional: Parents/legal guardians can also electronically sign the form by utilizing the "Fill and Sign" feature on Adobe Acrobat (Reader version or better). They can click "Add Signature," followed by "Draw," and use a mouse or their fingertip to sign.

The information completed in this sample form is an example only. It does not reflect an actual patient or healthcare provider.

HIPAA=Health Insurance Portability and Accountability Act.

Completing Page 5

Patient/Parent/Legal Guardian HIPAA Authorization (cont'd)

PRESCRIPTION AND ENROLLMENT FORM

acadia connect | Daybue (trofinetide) oral solution | Daybue Stix (trofinetide) for oral solution

Patient's Name: Jane Smith Date of Birth (MM/DD/YYYY): 01/01/2013

8 PATIENT/PARENT/LEGAL GUARDIAN AUTHORIZATION FOR DISCLOSURE OF HEALTH INFORMATION (cont)
(Please read and sign below if you agree.)

PROGRAM SIGN-UP & CONSENT TO PROCESS HEALTH INFO FOR PROGRAM PURPOSES (Required to participate in the Program)

I agree, on behalf of my child, for my child to enroll in Acadia Connect and, if my child is eligible, I agree for my child to enroll in the Program. I understand that any assistance with my cost-sharing or co-payment for DAYBUE will be made in accordance with the Program Terms and Conditions at <https://www.acadiaconnect.com/daybue/caregivers/about>.

I also agree that Acadia may collect and process health information about my child, including the details I provided on this form, information about my child's participation in the Program, and other health information about my child, such as my child's diagnosis, symptoms, medication, and inferences derived from the same, to facilitate my child's participation in the Program, including to investigate insurance benefits, eligibility, and coverage; provide financial assistance for copay or out-of-pocket payments; eligibility for free medication supply; coordinating care; coordinating the delivery of medication. I also agree that Acadia may contact me at the contact information I have provided on this form, including by calling or emailing me, for purposes related to my child's participation in the Program.

I understand that I am not required to consent to this processing of my child's health information. However, if I do not consent, my child will not be able to participate in the Program, as processing of my child's health information is necessary for Acadia to facilitate our participation in the Program.

If I consent, I have the right to withdraw consent on behalf of my child at any time by calling 844-737-2223 or mailing Acadia Connect, 1710 Shelby Oaks Dr. Ste 3, Memphis, TN 38134. For more information about Acadia's privacy practices, go to <https://acadia.com/en-us/legal-policies/privacy>. For additional privacy disclosures for California residents, go to <https://acadia.com/en-us/legal-policies/privacy#california>.

[Check Here](#) I consent

CONSENT TO RECEIVE TEXTS (Optional)

I agree that Acadia may contact me via text message at the above phone number regarding the Program and other Acadia products and services. I confirm that I am the subscriber for the mobile telephone number(s) I provided on this form, and I agree to notify Acadia promptly by calling 844-737-2223 or by mailing Acadia Connect, 1710 Shelby Oaks Dr. Ste 3, Memphis, TN 38134 if any of my numbers change in the future. I understand that my wireless service provider's message and data rates may apply. I can opt out of future communications by responding STOP to any text.

I UNDERSTAND THAT THESE COMMUNICATIONS MAY USE PRERECORDED/ARTIFICIAL VOICE MESSAGES AND/OR AN AUTOMATED SYSTEM AND THAT I DO NOT NEED TO AGREE TO RECEIVE CALLS OR TEXTS AS A CONDITION OF PURCHASING OR RECEIVING ANY GOODS OR SERVICES FROM ACADIA.

[Check Here](#) I consent
 I do not consent

AUTHORIZATION TO DISCLOSE INFORMATION TO INDIVIDUALS INVOLVED IN MY CARE (Optional)

I further authorize Acadia to discuss the coordination of my child's care with the family member(s) and/or caregiver(s) I list below. These individual(s) have my full permission to obtain and disclose personal and medical information about my child from Acadia.

Authorized Representative(s) (please print):
Name: John Smith Relationship to Patient: Father

Name: _____ Relationship to Patient: _____
[Sign Here](#) Patient/Parent/Legal Guardian: John Smith Date: 05/01/2025

Please submit completed enrollment form via fax to 1-888-385-2748 or email to DAYBUE@AcadiaConnect.com

ACADIA

©2026 Acadia Pharmaceuticals Inc. Acadia, Acadia Connect and DAYBUE are registered trademarks of Acadia Pharmaceuticals Inc. All rights reserved. DAY-US-0638-v3 03/26.

5 of 5

M

Include the patient's name and DOB at the top of every page.

N

The parent/legal guardian should read this section and select "I consent" in order to enroll the patient into Acadia Connect.

O

The parent/legal guardian should read this section and select their preferred option for receiving text messages from Acadia Connect.

P

Parents/legal guardians must read and sign this section.

Optional: Parents/legal guardians can also electronically sign the form by utilizing the "Fill and Sign" feature on Adobe Acrobat (Reader version or better). They can click "Add Signature," followed by "Draw," and use a mouse or their fingertip to sign.

The information completed in this sample form is an example only. It does not reflect an actual patient or healthcare provider.

Parents/legal guardians can provide consent using the **Acadia Connect Program Consent** or on the **DAYBUE and DAYBUE STIX Prescription and Enrollment Form**, which your office will submit to Acadia Connect.

HIPAA=Health Insurance Portability and Accountability Act.

Reference: 1. Acadia Pharmaceuticals Inc. DAYBUE [package insert]. San Diego, CA; 2025.